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are expressed as cost per quality adjusted life year (QALY) gained. Perspective is
that of the national health system (NHS). Benefits and costs were discounted with
3% per year. RESULTS: Over the 3 year analysis period, 2.12 life years per patient
were achieved with TA TAVI, 2.31 with TF TAVI and 1.51 with conservative medical
care, representing. 1.24, 1.38 and 0.74 QALYs, respectively. Cumulative direct costs
were predicted to amount to €37,311 and €35,689 with TA and TF TAVI, respectively
and to €23,103 with conservative care. Cost/QALY gained was €28,003 for TA TAVI
and €19,499 for TF TAVI, both ratios remaining well below the accepted willing-
ness-to-pay threshold for Spain. The substantial cost of the TAVI procedure was
largely offset over time mainly by savings related to prevented hospital readmis-
sions for cardiac reasons. Sensitivity analyses indicated these findings to be robust.
CONCLUSIONS: Compared to conservative management, TAVI is a life-saving and
cost-effective treatment for high-risk or inoperable patients with symptomatic
aortic valve stenosis in Spain.
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OBJECTIVES: The aim of this study was to combine clinical results from the RE-
VERSE study (Resynchronisation reverses Remodelling in Systolic Left Ventricular
Dysfunction) and costs associated with the addition of cardiac resynchronization
therapy (CRT) to optimal medical therapy (OMT) in patients with mild symptomatic
(NYHA I-II) or asymptomatic left ventricular dysfunction and markers of cardiac
dyssynchrony in Spain. METHODS: We developed a Markov model of CRT  OMT
(CRT-ON group) vs. OMT alone (CRT-OFF group) based on a retrospective cost-
effectiveness analysis. Raw data from the model was derived from literature and
expert opinion, reflecting clinical and economic consequences of patient’s man-
agement in Spain. Time horizon was 10 years, and costs were expressed in Euro
2010. Both costs and effects were discounted at 3% per annum. RESULTS: CRT-ON
group showed higher total costs than CRT-OFF, however patients with CRT reduced
94% the length of hospitalization in the ICU (0.006 vs. 0.091 days) and 34% in general
ward (0.705 vs. 1.076 days). Surviving patients with CRT-ON (88.2% vs. 77.5%) re-
mained in slighter functional class longer and they achieved an improvement of 0.9
life years (LYGs) and 0.77 years quality-adjusted life years (QALYs). In terms of cost
per LYGs, the results were €40,782 (5 years) and €18,431 (10 years), and in terms of
costs per QALYs gained were €39,800 and €21,500 at 5 and 10 years respectively.
Probabilistic sensitivity analysis showed that the probability of CRT-ON was cost-
effective is 65.54% at 10 years. CONCLUSIONS: The use of CRT added to OMT
represents an efficient use of resources in patients suffering from heart failure in
NYHA functional class I and II, with cost-effectiveness ratios below the Spanish
threshold at 10 years.
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OBJECTIVES: Case detection is key to identifying leprosy disease early in its devel-
opment for more effective prevention of progression to permanent disability. The
study evaluated the costs and cost-effectiveness of three leprosy case detection
methods in Nigeria’s north-eastern states of Adamawa and Gombe; namely Rapid
Village Survey (RVS), Household Contact Examination (HCE) and Traditional Heal-
er’s (THs) incentive approach METHODS: The study was cross-sectional and ex-
plorative, undertaken in routine practice setting, targeting endemic and non-en-
demic communities selected randomly. Primary and secondary data were collected
from routine practice records and the Nigerian Leprosy Elimination Programme
2009. All costs were measured from both providers’ and patients’ perspectives.
Effectiveness was measured as new cases detected and outcome expressed as cost
per case detected. Incremental approach, using routine passive case detection
method as a reference was used to estimate the costs and effects by comparing
each method against the routine practise; to measure additional cost per new case
detected, as incremental cost-effectiveness ratio (ICER). Univariate sensitivity
analysis was carried out to evaluate uncertainties around the ICER. All costs were
converted to US Dollars at the 2010 exchange rate. RESULTS:HCE generated a total
of $2416 at the lowest rate of $142 per additional case detected at all contact levels,
as the most cost-effective method while the RVS was dominated by THs method
which generated a total of $4447 at $193 per new case detected.Variation of diag-
nostic accuracy and subsistent wage for valuing unpaid time did not significantly
change the results. CONCLUSIONS: From both perspectives and at all contact lev-
els, the Household Contact Examination, complementing routine practice demon-
strated the most cost-effective approach to identifying new leprosy cases for effec-
tive prevention and control of leprosy in Nigeria. It will be necessary to carry out
implementation studies to establish the feasibility and acceptability of the method
in other leprosy areas.
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OBJECTIVES: To determine the cost-effectiveness of measuring glycated hemoglo-
bin with A1CNow ® compared with standard exam (SE) for DM2 patients, from the
Brazilian Private Healthcare System perspective. METHODS: The study was a cost-
effectiveness analysis based on Markov modeling to estimate costs and conse-
quences of treatments. Epidemiological and efficacy data derived from a critical
appraisal of the scientific literature. Only direct medical costs were considered. If
available, costs of clinical events (CE) were obtained from burden of disease stud-
ies. If not, Brazilian official guidelines were obtained to determine the resources
used to treat the CE. Drugs, hospital daily admission rates, procedures and labora-
tory tests unit costs were obtained from Brazilian official databases. Costs and
benefits were discounted at 5% yearly. Outcomes were expressed as CE avoided.
Probability sensitivity analysis (PSA) was conducted to assess model robustness.
Life time horizon was analyzed. RESULTS: Through the systematic review of the
literature the studies were selected to form the body of clinical data for the analy-
ses. The systematic review showed that although the absence of studies directly
evaluating the impact of A1CNow on cardiovascular events, their favorable influ-
ence on cardiovascular disease intermediate markers suggests that A1CNow may
have clinically relevant effect in patients at risk. The analysis showed higher clin-
ical benefits and lower costs for A1CNow. Considering 100 patients, 99.8 and 146.1
CE happen in A1CNow and SE arms, respectively. The average time-horizon cost
per patient was R$25,444(€11,108) and R$29,278(€12,782) for A1CNow and SE, re-
spectively, showing the dominance of A1CNow compared to SE. PSA demonstrated
that in 95.3% of the simulations A1CNow was dominant (more effective with lower
cost) compared to SE. CONCLUSIONS: Our study demonstrated that A1CNow have
clinically relevant effect in reducing CE being dominant for monitoring of glycated
hemoglobin in DM2 patients. PSA confirmed this determinist result.
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OBJECTIVES: Atrial Fibrillation (AF) is the most common arrhythmia among the
elderly. It has dire consequences, stroke being the most catastrophic. Its burden is
highly significant; changing demographics lead to more patients impacted. Man-
aging AF encompasses arrhythmia control and stroke prevention – with new tech-
nologies being developed for both. For Paroxysmal AF (PAF) – which terminates
spontaneously within 7 days – electrical Pulmonary Vein Isolation (PVI) has ad-
vanced as the cornerstone treatment in patients unresponsive to pharmaceuticals.
PAF accounts for 75% of patients, and half are medicated with sub-optimal out-
comes. We sought to evaluate the cost-effectiveness of PVI when using a new
balloon-based catheter using cooling energy for lesion creation (Arctic Front,
Medtronic). METHODS: A Markov Microsimulation Model compared treatment
with Arctic Front vs. conventional drugs. STOP-AF Pivotal Trial Data were used to
estimate PVI efficacy and complication rates. A literature review identified data for
long-term PVI and drug therapy outcomes. The model incorporated Arctic Front
specific complication rates (e.g. stroke, tamponade and phrenic nerve paralysis)
and drug toxicities and impact on stroke risk was included. Utility weights were
assigned for various health states. and a range of time horizons was used, with a UK
perspective adopted for costs and benefits. One-way and probabilistic sensitivity
analyses were undertaken. RESULTS: Depending on the time horizon, the ICER
ranged from £3,200/QALY to £15,700/QALY gained. Results were sensitive to as-
sumptions regarding long-term outcomes and the quality of life benefit of remain-
ing free of PAF. CONCLUSIONS: PVI can be highly cost-effective in treating PAF – a
highly prevalent and burdensome disease. Results are consistent with similar tech-
nology economic evaluations, and reinforce the evidence base for PVI as a cost-
effective therapy for PAF.
PMD31
ECONOMIC EVALUATION OF PRIMOVIST VERSUS EXTRACELLULAR CONTRAST
IN IMAGING OF LIVER METASTASES OF COLORECTAL ORIGIN
Castell J1, Bernal C1, De Marcos JÁ2, Cugat E2, Ramón E3, Tellado JM3
1Hospital Universitario Virgen del Rocío, Seville, Spain, 2Hospital Universitari Mútua de Terrassa,
Barcelona, Spain, 3Hospital G. U. Gregorio Marañón, Madrid, Spain
OBJECTIVES: The main purpose of this study was to conduct an economic evalua-
tion of Primovist enhanced MRI (PV-MRI) compared to extracellular contrast-me-
dia-enhanced MRI (ECC-MRI) in patients suffering from liver metastases of colo-
rectal origin in Spain. METHODS: An analytic model previously implemented in
three European countries (Germany, Italy and Sweden) was adapted in Spain to
estimate all aggregated costs of both diagnosis options compared. Probabilities of
needing further imaging and of needing surgical plans modification or confirma-
tion were adjusted by Spanish clinical experts (surgeons and radiologists). Con-
trasts cost was estimated from PTR (weighting the different EECs prices for sales in
Spain for this option), and tests (MRI and CT) and different surgery procedures (high
or low risk, modification or confirmation of surgical plans, etc.) costs were ex-
tracted from official fees of different Spanish Autonomous Communities (CCAA).
RESULTS: PV-MRI was associated with a reduced need for extra imaging tests (6%
vs. 9%). Taking into account the costs of diagnosis tests and surgery procedures
(including modification of surgical plans during intervention), PV-MRI option was a
cost-neutral strategy, with total costs similar to ECC-MRI (576 € vs. € 578, PV-MRI vs
ECC-MRI respectively). CONCLUSIONS: Additional costs associated with colorectal
liver metastases diagnosis with PV-MRI regarding to ECC-MRI are offset by lower
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costs in intraoperative changes of the surgical plan and reductions in unnecessary
surgery associated with the use of PV-MRI. Results from the previous study VALUE,
which showed that no patient with PV required additional imaging tests as part of
a Phase IV, confirm the results obtained in the present analysis (resulting in even
slightly lower cost than the total cost of diagnosis using PV-MRI).
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OBJECTIVES: Cervical cancer incidence in Serbia has been identified as one of the
highest in Europe, showing slow but steady increase during the last decade. De-
spite the National Programme for Prevention of Cervical Cancer that has recently
been established, an organised Pap screening is far from full implementation. This
study aims to assess the effectiveness and cost effectiveness of absolute adherence
to the proposed policy compared to the current practice. METHODS: A Markov
model simulating the natural history of cervical cancer was developed. Calibration
was performed using country specific data, sourcing incidence and mortality from
Serbian cancer registries. Accordingly, the screening algorithm incorporated in the
model was based on the local guidelines. We followed a hypothetical cohort of
100,000 15-year old girls until the end of their lifetime. Subsequently, the actual
cytological screening practice covering only 20% of the targeted population was
compared to a scenario of absolute adherence to the national screening pro-
gramme. A discount rate of 1.5% for health and 4% for cost outcomes was applied.
RESULTS: The natural history model showed that limited benefit is currently being
achieved from cytological screening. The hypothetical cohort analysis indicated
that absolute guidelines adherence would result in 422 deaths averted and an
incremental cost effectiveness ratio (ICER) of 3272 €/LYG. The ICER estimate did not
exceed the national annual GDP (3857 €/capita) - a commonly used informal
threshold. CONCLUSIONS: This research identified that full adherence to the
screening policy is very likely to be cost effective. In general, the low screening
coverage that has been observed appeared as the most serious obstacle to the
prevention of cervical cancer. The new methods in cervical cancer prevention,
however, such as HPV vaccination and HPV testing, require further pharmacoeco-
nomic assessment.
PMD33
ECONOMIC EVALUATION OF TWO WOUND DRESSINGS FOR CHILDREN WITH
PARTIAL-THICKNESS SCALDS FROM THE PUBLIC PAYER PERSPECTIVE
Tolentino ACM, Takemoto MLS, Fernandes RA, Cukier FN, Takemoto MMS, Cruz RB,
Ribeiro ACP, Fernandes RRA, Santos PML, Moretti AIP
ANOVA - Knowledge Translation, Rio de Janeiro, Brazil
OBJECTIVES: This study aimed to develop cost-effectiveness analysis of Soft Sili-
cone Wound-Contact Dressing (SS) versus Silver Sulphadiazine (SSD) in children
with partial-thickness scalds (PTS), under the perspective of Brazilian public
payers.METHODS: A literature search was conducted to gather efficacy data for SS
and SSD and identified one randomized controlled trial that compared median
time to 100% epithelialization (MTH) for SS and SSD. These data were used to
estimate clinical benefits in terms of “inpatient days avoided”. The model assumed
that SSD is the current practice in Brazilian public hospitals and patients are dis-
charged at the time their wound heals. Resource use was estimated through expert
panel, only direct medical costs were included in the analysis and unit costs were
obtained from Brazilian official price lists. RESULTS: The randomized trial ob-
served MTH of 10.5 and 27.6 days for SS and SSD, respectively (incremental effec-
tiveness of -17.1 days). Evidence from smaller observational studies have reported
intervals to SS change of up to 14 days, while SSD requires two changes per day.
Thus, the model estimated costs for the inpatient period assuming one dressing
change for SS and 28 changes for SSD. The cost per dressing change was estimated
as 33BRL for SS and 23BRL for SSD and the overall treatment costs were 1,261BRL
and 23BRL. SS-related incremental costs were -1228BRL indicating a cost-saving
profile. Benefits in terms of reduction in length of stay were not accounted in the
base case scenario. If average public hospital daily charges were included in the
cost estimation, savings would reach -2209BRL. CONCLUSIONS: SS dressing has
shown higher efficacy when compared to SSD, with fewer overall costs. The signif-
icant reduction in the median time to healing offset the higher unit cost by lower-
ing the number of required changes and the total length of stay.
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OBJECTIVES: A new ambulatory electrocardiogram (loop recorder) has been intro-
duced in Canada to detect arrhythmias, overcoming issues of previous recorders
with its capability of automatically detecting/sending electrocardiograph data and
simultaneously patient activation of device during symptoms. The loop recorder is
expected to have a higher diagnostic yield due to its recording capabilities and
longer test period (14days) however the cost is greater than the standard of care
(Holter). Cost-effectiveness was estimated for Holter versus the loop recorder for
diagnosing paroxysmal or persistent atrial fibrillation in primary physician care in
Ontario, Canada, from a health payer‘s perspective. METHODS: A probabilistic
decision analytic model was constructed to estimate cost, number of cases cor-
rectly detected, and number of strokes averted due to correct detection and treat-
ment over a 19 month period. Direct medical costs included diagnostic testing,
treatment of atrial fibrillation, prevention of stroke, and treatment of stroke. Costs
were expressed in 2011 Canadian dollars. One-way, multi-way and probabilistic
analyses of uncertainty were conducted. Model inputs were from various sources
including primary data, published literature and expert opinion.RESULTS:Average
cost was estimated at $490 for Holter, and $612 for loop recorder. Average cases of
atrial fibrillation correctly detected were 0.032 for Holter, and 0.058 for loop re-
corder. Average number of strokes averted were 0.010 for Holter and 0.018 for loop
recorder. The probabilistic mean incremental cost-effectiveness ratio of loop re-
corder versus Holter was $2430 per additional case correctly detected and $698 per
additional stroke averted. At a $20,000 willingness-to-pay threshold the probability
of the loop recorder being cost effective for cases detected and strokes averted were
95.5% and 60.4% respectively. Cases detected and strokes averted were 99.3% and
92% respectively for a willingness-to-pay of $50,000. CONCLUSIONS: Cost-effec-
tiveness analysis favours the new loop recorder compared to Holter.
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OBJECTIVES: The Corail™ Hip System, a hydroxyapatite coated cementless im-
plant, has demonstrated its high efficacy and safety for primary total hip arthro-
plasty (THA) for over 20 years. The objective of this work was to evaluate the
cost-effectiveness of the Corail™ Hip System in comparison with other cementless
hip designs (standard) in Spain. METHODS: An analytical decision-making model
was constructed as a Markov model for patients who were candidates to THA. The
study perspective was from the viewpoint of the Spanish National Health System
(NHS). Time horizons included in the model were 10 or 20 years and lifetime.
Healthcare costs associated with the compared interventions and their conse-
quences were expressed in euro 2011. Data came from a review of the literature and
was validated by local clinical experts. A discount rate of 3% was applied on costs
and efficacy data. RESULTS: The use of the Corail™ Hip System for THA compared
with the standard resulted in €4317 per revision avoided and €5812 per QALY
gained considering a time horizon of 10 years. The result was dominant in favour of
Corail™ when a time horizon of 20 years or lifetime was considered for all the
scores. Corail™ provided a gain of 0.075 QALY and saved €279 versus the standard
(lifetime). There were no significant differences between sexes. In the sensitivity
analysis was built the best scenario for Corail™ including the worse efficacy data
available for the standard and Corail™ resulted in a gain of 0.388 QALY and saved
€2226 (lifetime). The probabilistic sensitivity analysis showed that Corail™ was
cost-effective in 76% of cases (threshold of €30,000/QALY). CONCLUSIONS: Prelim-
inary results showed that the Corail™ Hip System is a cost-effective option in THA
compared with the rest of cementless hip trademarks available in Spain.
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OBJECTIVES: To compare the costs and effectiveness of the EX-PRESS glaucoma
filtration device (Alcon Inc, TX) to trabeculectomy, 5 years after surgery, in primary
open angle glaucoma (POAG). METHODS: Seventy-eight patients with POAG un-
controlled despite maximally-tolerated medical therapies were randomized to re-
ceive either the EX-PRESS or undergo a trabeculectomy, realized by a single sur-
geon. Outcomes captured over 5 years included intraocular pressure (IOP a
surrogate endpoint of glaucoma progression), use of IOP lowering medications and
additional eye surgeries. The economic perspective was the one of the Dutch Na-
tional Health System. Patients were considered a success if they had an IOP less
than or equal to the success thresholds of 15 or 18 mmHg, without IOP lowering
medications, and without having undergone further glaucoma surgery. Time to
failure was analyzed using a log rank test. Costs were discounted at a 4% rate.
EX-PRESS cost was not included. RESULTS: The 5-year failure rate was 41% for
EX-PRESS versus 69% for trabeculectomy (P0.005) using an 18 mmHg IOP target
and 46% versus 77% (P0.001) for 15 mmHg. EX-PRESS patients were less likely to
use medications, and among the medically treated patients, required fewer drugs.
EX-PRESS eyes required less needling (2 vs 5) and less cataract surgery (5 vs. 8).
Without discounting, drug savings with EX-PRESS equaled €333.86 and €107.79 for
eye surgery /laser, a total of €441.65. With a 4% discounting, the figures became
€310.45, €132.78 and €443.23, respectively. CONCLUSIONS: At 5 years after surgery,
EX-PRESS demonstrated that it better controls IOP than trabeculectomy, resulting
in savings in both IOP lowering drugs and eye surgeries. Economic benefits of the
better IOP control (less disease progression, i.e. a better vision) and saving accord-
ing to a lifelong time horizon will be estimated in future modelling exercises.
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OBJECTIVES: EX-PRESS glaucoma filtration device (Alcon Inc, TX) is an alternative
treatment to trabeculectomy, a surgery realized in advanced primary open angle
glaucoma (POAG). This analysis reports the incremental cost and benefits of
EX-PRESS. METHODS: Patients with POAG uncontrolled by maximally-tolerated
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